Reprimun--an antibiotic with large spectrum and immunomodulatory properties.
Reprimun contains an oxyminomethyl rifamycin-SV derivative as the active substance and has a large spectrum antibiotic activity, on Mycobacterium tuberculosis too. Reprimun also shows an inhibitory activity on viral and human lymphocyte reverse transcriptases, an antiproliferative effect on retrovirus, as well as a selective immunomodulator action at the level of TCD4+ lymphocyte. In animal, the toxicity tests demonstrated a good tolerance. In human subject, the drug is quite well tolerated: no severe adverse reactions were noted during and after its administration for 10-12 months. In man, Reprimun administration demonstrated a therapeutical effect in bacterial infections (tuberculosis included), sarcoidosis, immune thrombocytopenia, as well as in Kaposi's sarcoma. The drug is only for oral administration. It is well absorbed at the level of duodenum, achieving a repeated entero-hepatic circuit that provides a prolonged efficient concentration of Reprimun in blood serum. Like many other ansamycin derivatives, Reprimun can be given intermittently (e.g. twice or three times weekly). In case of antisarcoidosis therapy, Reprimun was applied with good results in 112 supervised cases, including 37 failures of a prior cortisone treatment its administration could be of a high benefit in HIV serum positive persons in which it can prevent both tuberculosis and HIV infection developments.
Păunescu
E
E
Marius Nasta Institute of Pneumophthisiology, Bucharest.
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001419:Bacteria / Q000187:drug effects; D004341:Drug Evaluation; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy; D007928:Lethal Dose 50; D051379:Mice; D008807:Mice, Inbred BALB C; D012294:Rifamycins / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D017565:Sarcoidosis, Pulmonary / Q000188:drug therapy; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D012294:Rifamycins; C062637:Reprimun